Skip to main content

Advertisement

SpringerLink
Log in

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Increasing evidence suggests that a high rate of bone turnover is associated with low bone mineral density (BMD) and is strongly linked to fracture risk. Measurement of biochemical markers of bone turnover is therefore becoming a more widely used endpoint in clinical trials in postmenopausal osteoporosis. This multinational double-blind, fracture-prevention study enrolled 2946 postmenopausal women with osteoporosis. Patients were randomized to receive placebo or oral ibandronate administered daily (2.5 mg/day) or intermittently (20 mg every other day for 12 doses every 3 months). The primary endpoint was the incidence of new vertebral fractures after 3 years. Secondary outcome measures included changes in the rate of bone turnover as assessed by biochemical markers and increases in spinal and hip BMD. Daily and intermittent oral ibandronate significantly reduced the risk of vertebral fractures by 62% and 50%, respectively, and produced significant and sustained reductions in all the measured biochemical markers of bone turnover. By 3 months, the rate of bone turnover was reduced by approximately 50–60%, and this level of suppression was sustained throughout the remainder of the study. In summary, oral ibandronate, given daily or with a between-dose interval of >2 months, normalizes the rate of bone turnover, provides significant increases in BMD and a marked reduction in the incidence of vertebral fractures. Thus, intermittent ibandronate has potential to become an important alternative to currently licensed bisphosphonates in postmenopausal osteoporosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Garnero P, Delmas PD (2001) Biochemical markers of bone turnover in osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis, vol 2. Academic Press, San Diego, pp 459–477

  2. Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929−1936

    Article  PubMed  Google Scholar 

  3. Ross PD, Kress BC, Parson RE et al. (2000) Serum bone alkaline phosphatase and calcaneus bone density predict fractures: a prospective study. Osteoporos Int 11:76−82

    Article  CAS  PubMed  Google Scholar 

  4. van Daele PLA, Seibel MJ, Burger H et al. (1996) Case-control analysis of bone resorption markers, disability and hip fracture risk: the Rotterdam study. BMJ 312:482−483

    PubMed  Google Scholar 

  5. Garnero P, Hausherr E, Chapuy M-C et al. (1996) Markers of bone resorption predict hip fracture in elderly women: the EPIDOS prospective study. J Bone Miner Res 11:1531−1538

    CAS  PubMed  Google Scholar 

  6. Hansen MA, Overgaard K, Riis BJ, Christiansen C (1991) Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 303:961−964

    CAS  PubMed  Google Scholar 

  7. Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD (2000) Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study. J Bone Miner Res 15:1526−1536

    CAS  PubMed  Google Scholar 

  8. Marcus R, Wong M, Heath H III, Stock JL (2002) Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes with fracture as endpoint. Endocr Rev 23:16−37

    CAS  Google Scholar 

  9. Hochberg MC, Ross PD, Black D et al. (1999) Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42:1246−1254

    Article  CAS  PubMed  Google Scholar 

  10. Wasnich RD, Miller PD (2000) Antifracture efficacy of antiresorptive agents is related to changes in bone density. J Clin Endocrinol Metab 85:231−236

    Article  CAS  PubMed  Google Scholar 

  11. Siris ES, Miller PD, Barrett-Connor E et al. (2001) Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women. Results from the National Osteoporosis Risk Assessment. JAMA 286:2815−2822

    CAS  PubMed  Google Scholar 

  12. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254−1259

    CAS  PubMed  Google Scholar 

  13. Ravn P (2001) Prediction of response in bone mass by biochemical markers of bone turnover during antiresorptive therapy for prevention of osteoporosis. In: Eastell R, Baumann M, Hoyle NR, Wieczorek L (eds) Bone markers: biochemical and clinical perspectives; Martin Dunitz, London, pp 167−178

  14. Gundberg CM (2001) Osteocalcin. In: Eastell R, Baumann M, Hoyle NR, Wieczorek L (eds) Bone markers: biochemical and clinical perspectives. Martin Dunitz, London; pp 65−72

  15. Delmas PD (2002) Treatment of postmenopausal osteoporosis. Lancet 359:2018–2026

    Article  CAS  PubMed  Google Scholar 

  16. Black DM, Cummings SR, Karpf DB et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541

    CAS  PubMed  Google Scholar 

  17. Cummings SR, Black DM, Thompson DE et al. (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fracture. JAMA 280:2077–2082

    CAS  PubMed  Google Scholar 

  18. Harris ST, Watts NB, Genant HK et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomised controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344–1352

    CAS  PubMed  Google Scholar 

  19. Reginster J, Minne HW, Sorenson OH et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83–91

    CAS  PubMed  Google Scholar 

  20. McClung MR, Geusens P, Miller PD et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333–340

    Article  CAS  PubMed  Google Scholar 

  21. Schnitzer T, Bone HG, Crepaldi G et al. (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 12:1–12

    CAS  Google Scholar 

  22. Riis BJ, Ise J, Von Stein T, Bagger Y, Christiansen C (2001) Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 16:1871−1878

    CAS  PubMed  Google Scholar 

  23. Thiébaud D, Burckhardt P, Kriegbaum H et al. (1997) Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 103:298−307

    CAS  PubMed  Google Scholar 

  24. Reid IR, Brown JP, Burckhardt P et al. (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653−661

    Article  CAS  Google Scholar 

  25. Kendler DL, Diez-Perez A, Gaines KA, Verbruggen N, Melton ME (2002) Patient preference of once weekly or daily administration of alendronate (Fosamax) for osteoporosis: a randomized cross-over study. Osteoporos Int 13:S32 (Abstract P92SA)

    Google Scholar 

  26. Palmisano J, Melton M, Lewiecki EM et al. (2002) Preference study of alendronate 70 mg once weekly and alendronate 10 mg once daily in postmenopausal women with osteoporosis. Osteoporos Int 13:S36 (Abstract P103MO)

    Google Scholar 

  27. Chesnut III CH, Skag A, Christiansen C et al. (2004) Oral ibandronate significantly reduces fracture risk in postmenopausal osteoporosis when administered daily or with a between-dose interval greater than 2 months: results from the BONE study. J Bone Miner Res (in press)

  28. Garnero P, Sornay-Rendu E, Chapuy M-C, Delmas PD (1996) Increased bone turnover in late menopausal women is a major determinant of osteoporosis. J Bone Miner Res 11:337–349

    CAS  PubMed  Google Scholar 

  29. Russell RGG, Croucher PI, Rogers MJ (1999) Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos Int 9:S66−S80

    PubMed  Google Scholar 

  30. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693−1700

    CAS  PubMed  Google Scholar 

  31. Harris ST, Gertz BJ, Genant HK et al. (1993) The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 76:1399−1406

    CAS  PubMed  Google Scholar 

  32. Harris ST, Eriksen EF, Davidson M et al. (2001) Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 86:1890−1897

    CAS  PubMed  Google Scholar 

  33. Raisz L, Smith JA, Trahiotis M et al. (2000) Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover. Osteoporos Int 11:615−620

    Article  CAS  PubMed  Google Scholar 

  34. Reginster JY, Minne HW, Sorensen OH et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83−91

    CAS  PubMed  Google Scholar 

  35. Eastell R, Barton I, Hannon RA et al. (2003) Relationship of early changes in bone resorption to reduction of fracture risk with risedronate. J Bone Miner Res 18:1051–1056

    CAS  PubMed  Google Scholar 

  36. Bauser DC, Black DM, Garnero P et al. (2000) Reduction in bone turnover predicts hip, non-spine, and vertebral fracture in alendronate treated women: the Fracture Intervention Trial. Osteoporos Int 13:521

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Inserm Unite 403, Physiopathologie, Hôpital Edouard Herriot, 5 Place D’Arsonval, Lyon Cedex 3, France

    P. D. Delmas

  2. Creighton University, Omaha, Neb., USA

    R. R. Recker

  3. Osteoporosis Research Group, University of Washington, Seattle, Wash., USA

    C. H. Chesnut III

  4. Center for Clinical Trials, Hamar, Norway

    A. Skag

  5. CECOR AS, Haugesund, Norway

    J. A. Stakkestad

  6. Radiant Research, Wyomissing, Penn., USA

    R. Emkey

  7. Roche Products Ltd, Welwyn Garden City, UK

    J. Gilbride

  8. F. Hoffmann-La Roche Ltd, Basel, Switzerland

    R. C. Schimmer

  9. CCBR, Ballerup, Denmark

    C. Christiansen

Authors
  1. P. D. Delmas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. R. Recker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. H. Chesnut III
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Skag
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. A. Stakkestad
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Emkey
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. Gilbride
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. R. C. Schimmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C. Christiansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

For the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE)

Corresponding author

Correspondence to P. D. Delmas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Delmas, P.D., Recker, R.R., Chesnut, C.H. et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15, 792–798 (2004). https://doi.org/10.1007/s00198-004-1602-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-004-1602-9

Keywords

Search

Navigation